Related Experiment Video
Updated: Jun 4, 2026
11:17
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients
Jung Ran Choi1, Jeong-Oh Kim, Dae Ryong Kang
1Laboratory of Medical Oncology, Catholic Research Institutes of Medical Science, The Catholic University of Korea, Seoul, Republic of Korea.
Journal of Human Genetics
|February 18, 2011
Summary
Genetic factors and clinical data significantly influence warfarin dosing in Korean patients. This study identifies key gene variations and patient characteristics to optimize anticoagulant therapy for improved safety and efficacy.
Area of Science:
- Pharmacogenomics
- Clinical Pharmacology
- Genetics
Background:
- Warfarin is a critical anticoagulant for preventing thromboembolic disorders.
- Individual warfarin dose requirements vary significantly.
- Genetic and clinical factors are known to influence warfarin response.
Purpose of the Study:
- To investigate the impact of genetic variations in VKORC1, CYP2C9, CYP4F2, and GGCX, along with clinical factors, on warfarin dose requirements in Korean patients.
- To develop a warfarin-dosing algorithm tailored for the Korean population based on these variables.
Main Methods:
- Analysis of single nucleotide polymorphisms (SNPs) in VKORC1, CYP2C9, CYP4F2, and GGCX in 564 Korean patients.
- Multiple regression analysis was employed to build a predictive model for warfarin dosage.
- Correlation between genetic polymorphisms, clinical factors (age, gender, BSA, INR), and warfarin dose was assessed.
Main Results:
- Significant correlations were found between SNPs in VKORC1, CYP2C9, CYP4F2, and GGCX and warfarin dose requirements.
- Specific genotypes (e.g., 3730AA for VKORC1, wild-type for CYP2C9) were associated with higher warfarin doses.
- A multiple regression model incorporating age, gender, BSA, INR, and four genetic polymorphisms explained 35% of the variation in warfarin dose (R²=0.3499).
Conclusions:
- Age, gender, body surface area (BSA), international normalized ratio (INR), and polymorphisms in VKORC1, CYP2C9, and CYP4F2 are key determinants of warfarin dose in Koreans.
- Incorporating these genetic and clinical factors into clinical guidelines can enhance the efficacy and safety of warfarin treatment for Korean patients.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...